GSK PLC Sponsored ADR (NYSE:GSK) Given Consensus Recommendation of “Reduce” by Brokerages

GSK PLC Sponsored ADR (NYSE:GSK) has received a consensus rating of “Reduce” from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $44.1250.

GSK has been the topic of a number of recent research reports. Cfra set a $53.00 price objective on GSK in a research report on Thursday, October 30th. Barclays downgraded GSK from an “equal weight” rating to an “underweight” rating in a research report on Tuesday, January 6th. Jefferies Financial Group reaffirmed a “buy” rating on shares of GSK in a research note on Monday, October 27th. Weiss Ratings reiterated a “buy (b)” rating on shares of GSK in a research report on Monday, December 29th. Finally, Morgan Stanley restated an “underweight” rating on shares of GSK in a report on Wednesday.

Insider Buying and Selling at GSK

In other GSK news, major shareholder Plc Gsk purchased 1,470,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average cost of $19.00 per share, with a total value of $27,930,000.00. Following the purchase, the insider owned 18,245,691 shares of the company’s stock, valued at approximately $346,668,129. The trade was a 8.76% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.

Institutional Trading of GSK

Institutional investors and hedge funds have recently made changes to their positions in the business. Fisher Asset Management LLC grew its holdings in shares of GSK by 4.4% in the second quarter. Fisher Asset Management LLC now owns 31,338,405 shares of the pharmaceutical company’s stock worth $1,203,395,000 after purchasing an additional 1,306,590 shares during the last quarter. Quantbot Technologies LP boosted its position in GSK by 184.6% in the 2nd quarter. Quantbot Technologies LP now owns 138,898 shares of the pharmaceutical company’s stock valued at $5,334,000 after buying an additional 90,097 shares during the period. TD Private Client Wealth LLC grew its stake in GSK by 997.5% in the 2nd quarter. TD Private Client Wealth LLC now owns 78,019 shares of the pharmaceutical company’s stock worth $2,996,000 after acquiring an additional 70,910 shares in the last quarter. Sound Income Strategies LLC increased its position in shares of GSK by 7.3% during the second quarter. Sound Income Strategies LLC now owns 431,256 shares of the pharmaceutical company’s stock worth $16,560,000 after acquiring an additional 29,197 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S raised its stake in shares of GSK by 28.2% during the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company’s stock valued at $4,656,000 after acquiring an additional 26,685 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

GSK stock opened at $48.26 on Friday. GSK has a 52-week low of $32.38 and a 52-week high of $51.46. The company has a market cap of $98.37 billion, a price-to-earnings ratio of 13.63, a PEG ratio of 1.23 and a beta of 0.45. The firm’s fifty day moving average is $48.58 and its 200 day moving average is $43.46. The company has a quick ratio of 0.55, a current ratio of 0.84 and a debt-to-equity ratio of 0.95.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.22. GSK had a net margin of 17.16% and a return on equity of 48.64%. The firm had revenue of $11.35 billion for the quarter, compared to the consensus estimate of $8.21 billion. During the same period in the previous year, the firm posted $0.50 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Sell-side analysts forecast that GSK will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 8th. Shareholders of record on Friday, November 14th were given a dividend of $0.4171 per share. This represents a $1.67 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Friday, November 14th. GSK’s payout ratio is 48.02%.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.